Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hemab Therapeutics Holdings, Inc.COAG · Entity 4476 | Chief Medical Officer | January 29, 2026 | May 04, 2026 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Chief Medical Officer | February 02, 2023 | February 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hemab Therapeutics Holdings, Inc.
Report date January 29, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2036-01-28 | Direct | 145,134 |
Reported balance
After 2026-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-29 · Grant · Acquired 145,134 · Balance 145,134 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29 | Direct | 49,016 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 49,016 · Balance 49,016 F2: This option was granted on April 30, 2026. The shares underlying the option will vest over four years in equal monthly installments from May 1, 2026 through May 1, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter.
F2: This option was granted on April 30, 2026. The shares underlying the option will vest over four years in equal monthly installments from May 1, 2026 through May 1, 2030.
Syndax Pharmaceuticals Inc
Report date February 02, 2023 · Filed February 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.55 · Expires 2033-02-02 | Direct | 110,000 |
Reported balance
After 2023-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-02 · Grant · Acquired 110,000 · Balance 110,000 F1: 1/48th of the shares subject to the option shall vest monthly over a four-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest monthly over a four-year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2026 Filed May 4, 2026 20:18 UTC | Hemab Therapeutics Holdings, Inc. COAG · Entity 4476 | GrantStock Option (Right to Buy) · Derivative | 49,016 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-204041 · ownership.xml · derivative · entry 2 Madigan Catherine · CIK 0001914577 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,016 Underlying: Common Stock · 49,016 shares Expires 2036-04-29 F2 · derivative.exercise_date: This option was granted on April 30, 2026. The shares underlying the option will vest over four years in equal monthly installments from May 1, 2026 through May 1, 2030. Read SEC document |
| January 29, 2026 Filed May 4, 2026 20:18 UTC | Hemab Therapeutics Holdings, Inc. COAG · Entity 4476 | GrantWarrants (Right to Buy) · Derivative | 145,134 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001193125-26-204041 · ownership.xml · derivative · entry 1 Madigan Catherine · CIK 0001914577 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,134 Underlying: Common Stock · 145,134 shares Expires 2036-01-28 F1 · derivative.exercise_date: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly installments thereafter. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:01 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 110,000 | $28.55 Strike: $28.55 | $3,140,500.00 |
DisclosureSEC source: 0001562180-23-000954 · primarydocument.xml · derivative · entry 1 Madigan Catherine · CIK 0001914577 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:24 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 180,000 | $16.06 Strike: $16.06 | $2,890,800.00 |
DisclosureSEC source: 0001562180-22-002258 · primarydocument.xml · derivative · entry 1 Madigan Catherine · CIK 0001914577 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: Twenty five percent (25%) of the total number of shares underlying the option shall vest on March 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.